Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation

Mark Crowther, Alison Avenell, D. J. Culligan

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patient demographics and glutamine administration schedule. Many of the studies were small and scored poorly on methodological quality. Oral glutamine may reduce mucositis (average mucositis score: standard mean difference -0.38, 95% confidence interval (CI) -0.59 to -0.16) and days of opioids (mean difference -1.95 days, 95% CI -3.66 to -0.25) and GVHD (relative risk 0.42, 95% CI 0.21-0.85). Glutamine (i.v.) may reduce clinical infections (relative risk 0.75, 95% CI 0.58 to 0.97) and positive cultures (relative risk 0.72, 95% CI 0.57-0.91) but may also increase the risk of relapse (relative risk 2.91, 95% CI 1.34-6.29) but this is based on only two small studies. There was no effect of oral or i.v. glutamine on overall transplant-related mortality at day + 100. In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects. Bone Marrow Transplantation (2009) 44, 413 - 425; doi: 10.1038/bmt.2009.41; published online 9 March 2009

Original languageEnglish
Pages (from-to)413-425
Number of pages13
JournalBone Marrow Transplantation
Volume44
Issue number7
Early online date9 Mar 2009
DOIs
Publication statusPublished - Oct 2009

Keywords

  • glutamine
  • meta-analysis
  • transplant
  • bone-marrow-transplantation
  • parenteral nutritional support
  • versus-host-disease
  • dose oral glutamine
  • double-blind
  • placebo
  • reccomendations
  • malignancies
  • mucositis
  • efficacy

Cite this

Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. / Crowther, Mark; Avenell, Alison; Culligan, D. J.

In: Bone Marrow Transplantation, Vol. 44, No. 7, 10.2009, p. 413-425.

Research output: Contribution to journalArticle

@article{a3dd7f7c5fb44d80a6f0845f330b2487,
title = "Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation",
abstract = "It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patient demographics and glutamine administration schedule. Many of the studies were small and scored poorly on methodological quality. Oral glutamine may reduce mucositis (average mucositis score: standard mean difference -0.38, 95{\%} confidence interval (CI) -0.59 to -0.16) and days of opioids (mean difference -1.95 days, 95{\%} CI -3.66 to -0.25) and GVHD (relative risk 0.42, 95{\%} CI 0.21-0.85). Glutamine (i.v.) may reduce clinical infections (relative risk 0.75, 95{\%} CI 0.58 to 0.97) and positive cultures (relative risk 0.72, 95{\%} CI 0.57-0.91) but may also increase the risk of relapse (relative risk 2.91, 95{\%} CI 1.34-6.29) but this is based on only two small studies. There was no effect of oral or i.v. glutamine on overall transplant-related mortality at day + 100. In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects. Bone Marrow Transplantation (2009) 44, 413 - 425; doi: 10.1038/bmt.2009.41; published online 9 March 2009",
keywords = "glutamine, meta-analysis, transplant, bone-marrow-transplantation, parenteral nutritional support, versus-host-disease, dose oral glutamine, double-blind, placebo, reccomendations, malignancies, mucositis, efficacy",
author = "Mark Crowther and Alison Avenell and Culligan, {D. J.}",
year = "2009",
month = "10",
doi = "10.1038/bmt.2009.41",
language = "English",
volume = "44",
pages = "413--425",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation

AU - Crowther, Mark

AU - Avenell, Alison

AU - Culligan, D. J.

PY - 2009/10

Y1 - 2009/10

N2 - It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patient demographics and glutamine administration schedule. Many of the studies were small and scored poorly on methodological quality. Oral glutamine may reduce mucositis (average mucositis score: standard mean difference -0.38, 95% confidence interval (CI) -0.59 to -0.16) and days of opioids (mean difference -1.95 days, 95% CI -3.66 to -0.25) and GVHD (relative risk 0.42, 95% CI 0.21-0.85). Glutamine (i.v.) may reduce clinical infections (relative risk 0.75, 95% CI 0.58 to 0.97) and positive cultures (relative risk 0.72, 95% CI 0.57-0.91) but may also increase the risk of relapse (relative risk 2.91, 95% CI 1.34-6.29) but this is based on only two small studies. There was no effect of oral or i.v. glutamine on overall transplant-related mortality at day + 100. In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects. Bone Marrow Transplantation (2009) 44, 413 - 425; doi: 10.1038/bmt.2009.41; published online 9 March 2009

AB - It is unclear whether supplemental glutamine is of benefit in haematopoietic stem cell transplantation (HSCT). We performed a systematic review and meta-analyses using Cochrane methodology. Seventeen randomized controlled trials (RCTs) were found. There was considerable heterogeneity between studies in terms of patient demographics and glutamine administration schedule. Many of the studies were small and scored poorly on methodological quality. Oral glutamine may reduce mucositis (average mucositis score: standard mean difference -0.38, 95% confidence interval (CI) -0.59 to -0.16) and days of opioids (mean difference -1.95 days, 95% CI -3.66 to -0.25) and GVHD (relative risk 0.42, 95% CI 0.21-0.85). Glutamine (i.v.) may reduce clinical infections (relative risk 0.75, 95% CI 0.58 to 0.97) and positive cultures (relative risk 0.72, 95% CI 0.57-0.91) but may also increase the risk of relapse (relative risk 2.91, 95% CI 1.34-6.29) but this is based on only two small studies. There was no effect of oral or i.v. glutamine on overall transplant-related mortality at day + 100. In conclusion, there may be beneficial effects of glutamine in HSCT but larger, well-designed studies are required to confirm the beneficial effects and investigate possible adverse effects. Bone Marrow Transplantation (2009) 44, 413 - 425; doi: 10.1038/bmt.2009.41; published online 9 March 2009

KW - glutamine

KW - meta-analysis

KW - transplant

KW - bone-marrow-transplantation

KW - parenteral nutritional support

KW - versus-host-disease

KW - dose oral glutamine

KW - double-blind

KW - placebo

KW - reccomendations

KW - malignancies

KW - mucositis

KW - efficacy

U2 - 10.1038/bmt.2009.41

DO - 10.1038/bmt.2009.41

M3 - Article

VL - 44

SP - 413

EP - 425

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -